CTS Chemical Industries
This article was originally published in The Tan Sheet
Executive Summary
Company withdraws citizen petition requesting GRAS status for use of echinacea extract as binding agent in certain solid-dosage form drugs, FDA acknowledges in Oct. 3 letter to Israeli pharmaceutical firm's New Jersey-based consultant. CTS filed a petition in September 2000 proposing use of the extract, in amounts of 3 mg-30 mg per dosage unit, in cough/cold remedies, antidiarrheal agents, analgesics, antibiotics (1"The Tan Sheet" Sept. 18, 2000, p. 3)
You may also be interested in...
Echinacea Extract GRAS Status For Binding Agent In Drugs Requested
An Israeli pharmaceutical firm is seeking GRAS status for use of echinacea extract as a binding agent in certain solid-dosage form OTC and Rx drugs intended for short-term use.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands